Navigation Links
Sinovac to Host Conference Call to Report First Quarter 2009 Financial Results
Date:5/8/2009

BEIJING, May 8 /PRNewswire-FirstCall/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that it will host a conference call on Friday, May 15, 2009 at 9:00 a.m. ET to review the Company's first quarter financial results for the period ended March 31, 2009 and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call will be available from 12:00 p.m. ET on May 15, until May 29, 2009 at midnight. To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415 (international) and reference the account number 3055 and the access code 322891.

A live audio webcast of the call will also be available from the Investors section on the corporate web site at www.sinovac.com. A webcast replay can be accessed on the corporate website beginning May 15, 2009 and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for Enterovirus 71, Universal Pandemic Influenza, Japanese encephalitis vaccine, and Human Rabies vaccine. Its wholly-owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

    Contact Information:            
'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
2. Sinovac Initiates Preparatory Activities for Swine Flu Vaccine
3. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results with Financial Tables
4. Sinovac Reports Unaudited Full Year 2008 and Fourth Quarter Financial Results
5. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2008 Financial Results
6. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
7. Sinovac Receives GMP Certification for its New Filling and Packaging Production Facility
8. Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine
9. Sinovac Releases Statement on Healive Vaccine Suspension
10. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
11. Sinovac Named to Deloitte Technology Fast 50 China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ... Therapy Market, 2015 - 2025" report to their ... report provides an extensive study on the marketed and ... carried out in this field for over a decade ... in Asian markets; one approved in the EU). There ...
(Date:3/3/2015)... California (PRWEB) March 03, 2015 Crown ... service company, has launched a new Life Science division ... for preclinical research. , The first products released ... isotype controls, and soon to be released in vivo ... will continue to expand their life science portfolio with ...
(Date:3/3/2015)... March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... scientific journal, Expert Opinion on Biological Therapy , ... Zhenggang Zhang , at the Henry Ford Hospital ... Thymosin beta 4 (TB4) has the capacity to promote ... or more post-injury, leading to neurological recovery in each ...
(Date:3/3/2015)... Liberty Corner, New Jersey (PRWEB) March 03, 2015 ... in NJ, has announced today that it has ... DE. Terms of the transaction were not ... engineering consulting services to the energy sector including ... gas, alternative energy, and fossil and nuclear power ...
Breaking Biology Technology:Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... NATICK, Mass., Nov. 9, 2010 Boston Scientific Corporation ... implantation of its Vercise™ Deep Brain Stimulation (DBS) System ... a multi-center, prospective trial designed to examine the improvement ... with the Vercise DBS System for the treatment of ...
... Life Sciences Holdings, Inc. (OTC Bulletin Board: ... discovery, development and commercialization of novel drugs in the ... announced that it has submitted a full proposal to ... under BAA-NIAID-DMID-NIHAI2010097 Development Of Therapeutics For Biodefense . ...
... Professor Andre Geim, who along with his colleague Professor ... the world,s thinnest material, has now modified it ... to Teflon. Fluorographene is fully-fluorinated graphene and is ... including chemical inertness and thermal stability. The ...
Cached Biology Technology:Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 2Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 3Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 4Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 2Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 3Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 4Graphene gets a Teflon makeover 2Graphene gets a Teflon makeover 3
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... to a report issued last week by UNAIDS, access ... worldwide. But Dr. Groesbeck Parham, gynecologic oncologist and ... Center for Infectious Disease Research in Zambia (CIDRZ) warns ... dying of cervical cancer unless they have access to ...
... at The University of Manchester have developed a new x-ray ... and human cancers more effectively. Professor Robert Cernik and ... colour 3D X-ray system that allows material at each point ... work is reported in the latest issue of The Journal ...
... for commercial genetic testing is on the rise and ... (MGH) physician. In the December issue of Obstetrics ... testing is poorly regulated and may present potential pitfalls ... that are being offered have no proven clinical validity ...
Cached Biology News:Women with AIDS face cervical cancer threat 2New X-ray technique targets terrorists and tumors 2Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Fibulin-2 (D-15)...
Biology Products: